Payment overview · 2025
General Payments
$23.08
1 reported records · 1 companies
Healthcare provider profile · identity verified
Alan Markie, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · PASADENA, CA · NPI 1861475337
Verified facts
What the public records show
CMS Open Payments records show Alan Markie, M.D. received $23.08 in general payments during 2025 across 1 reported records.
Lundbeck LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Abilify Maintena by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.08 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $23.08 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Olanzapine | Olanzapine | 2277 | 210 |
| Clozapine | Clozapine | 1818 | 93 |
| Olanzapine Odt | Olanzapine | 1521 | 109 |
| Quetiapine Fumarate | Quetiapine Fumarate | 1511 | 137 |
| Divalproex Sodium | Divalproex Sodium | 980 | 107 |
| Benztropine Mesylate | Benztropine Mesylate | 966 | 105 |
| Haloperidol | Haloperidol | 832 | 82 |
| Risperidone | Risperidone | 749 | 87 |
| Lorazepam | Lorazepam | 742 | 120 |
| Escitalopram Oxalate | Escitalopram Oxalate | 661 | 64 |
| Risperidone Odt | Risperidone | 650 | 50 |
| Trazodone Hcl | Trazodone Hcl | 591 | 88 |
| Divalproex Sodium Er | Divalproex Sodium | 572 | 61 |
| Invega Sustenna | Paliperidone Palmitate | 530 | 69 |
| Clonazepam | Clonazepam | 496 | 45 |
| Mirtazapine | Mirtazapine | 490 | 57 |
| Lithium Carbonate | Lithium Carbonate | 469 | 37 |
| Gabapentin | Gabapentin | 401 | 45 |
| Sertraline Hcl | Sertraline Hcl | 399 | 40 |
| Clozapine Odt | Clozapine | 388 | 26 |
| Haloperidol Decanoate | Haloperidol Decanoate | 360 | 40 |
| Aripiprazole | Aripiprazole | 338 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 320 | 31 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 289 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 36 |
| Temazepam | Temazepam | 270 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 24 |
| Aripiprazole Odt | Aripiprazole | 242 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 28 |
| Metformin Hcl | Metformin Hcl | 222 | 30 |
| Doxepin Hcl | Doxepin Hcl | 215 | 19 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 209 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 204 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 203 | 21 |
| Buspirone Hcl | Buspirone Hcl | 196 | 23 |
| Lactulose | Lactulose | 181 | 21 |
| Atropine Sulfate | Atropine Sulfate | 176 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 168 | 15 |
| Lurasidone Hcl | Lurasidone Hcl | 155 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 146 | 13 |
| Propranolol Hcl | Propranolol Hcl | 118 | 13 |
| Levetiracetam | Levetiracetam | 113 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 99 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 99 | 23 |
| Topiramate | Topiramate | 96 | 11 |
| Carbamazepine | Carbamazepine | 93 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 11 |
| Lamotrigine | Lamotrigine | 86 | 11 |
| Fluphenazine Hcl | Fluphenazine Hcl | 82 | suppressed |
| Paliperidone Er | Paliperidone | 82 | suppressed |
| Austedo | Deutetrabenazine | 80 | 11 |
| Losartan Potassium | Losartan Potassium | 79 | suppressed |
| Lisinopril | Lisinopril | 75 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 74 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 68 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 67 | suppressed |
| Fenofibrate | Fenofibrate | 66 | suppressed |
| Simvastatin | Simvastatin | 65 | suppressed |
| Valproic Acid | Valproic Acid | 65 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 62 | suppressed |
| Famotidine | Famotidine | 62 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 59 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 11 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 53 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | suppressed |
| Loxapine | Loxapine Succinate | 43 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Abilify Maintena | Aripiprazole | 38 | suppressed |
| Omeprazole | Omeprazole | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 36 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 35 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 34 | suppressed |
| Furosemide | Furosemide | 34 | suppressed |
| Ibu | Ibuprofen | 34 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 22 | 19 |
| Naltrexone Hcl | Naltrexone Hcl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 17 | suppressed |
| Norethindrone | Norethindrone | 17 | suppressed |
| Perphenazine | Perphenazine | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23.08 · 1 records | Lundbeck LLC | REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error